Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$6380.00
-50.00 (-0.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $7.1B · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$180.8B
P/E
28.0x
↑EV/EBITDA
13.0x
↑ROE
13.2%
↑Gross Margin
36.9%
↓Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.0%
FCF CAGR
+6.5%
FCF margin
23.5%
FCF / Net income
1.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $38.57B · net income $6.48B · FCF $9.06B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $38.57B | $38.57B | $35.60B | $34.70B | $32.42B |
| Net Income | $6.48B | $6.48B | $7.99B | $4.00B | $-2.60B |
| EBITDA | $14.59B | $14.59B | $12.22B | $11.18B | $6.11B |
| EPS | 228.00 | 228.00 | 298.00 | 150.00 | -97.00 |
| Gross Margin | 36.9% | 36.9% | 34.4% | 34.0% | 26.8% |
| Operating Margin | 19.3% | 19.3% | 14.3% | 15.1% | 4.8% |
| Net Margin | 16.8% | 16.8% | 22.5% | 11.5% | -8.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.41 | 1.00 | 1.54 |
| Current Ratio | 1.70 | 1.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $9.06B | $9.06B | $5.16B | $7.14B | $7.51B |
| Returns | |||||
| ROE | 13.2% | 13.2% | 18.6% | 18.4% | -14.8% |
| Valuation | |||||
| P/E | 27.98 | 27.98 | 26.74 | 38.00 | — |
| EV/EBITDA | 13.05 | 13.05 | 18.06 | 15.37 | 25.96 |
| P/B | 3.68 | 3.68 | 4.97 | 6.98 | 7.62 |
| Growth & Yield | |||||
| Revenue Growth | 8.3% | 8.3% | 2.6% | 7.0% | — |
| EPS Growth | -23.5% | -23.5% | 98.7% | 254.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.4%
EPS terminal req.
$566.12
Spread vs growth
-58.9%
5Y implied EPS CAGR
24.6%
EPS terminal req.
$685.00
Spread vs growth
-48.1%
10Y implied EPS CAGR
17.1%
EPS terminal req.
$1103.21
Spread vs growth
-40.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-36.0%
Start / end P/E
33.5x → 28.0x
EPS bridge
298.00 → 228.00
Residual
+3.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.